邱际亮 职务：
职称：博士，副主任医师、硕士生导师
专长：肝癌的外科治疗、介入治疗、靶向免疫治疗等，肝转移的外科治疗

主要简介 详细介绍 预约挂号

基本情况
职称：博士，副主任医师、硕士生导师
专业特长：肝癌的外科治疗、介入治疗、靶向免疫治疗等，肝转移的外科治疗。

学术兼职：
广东省抗癌协会肝癌专业委员会青委会 委员
广东省抗癌协会大肠癌专业委员会青委会 委员

工作概况：
　　自2007年以来，长期从事肝癌的临床诊治及相关研究工作，熟练掌握包括外科治疗、介入治疗、靶向治疗、免疫治疗等综合治疗手段。积极推进肝癌的临床研究开展，尤其是在不可切除肝癌的手术转化治疗、复杂疑难肝癌的综合治疗具有较为丰富的临床工作积累。在肠癌肝转移瘤的外科治疗方面，已有相当丰富的工作经验。


基本情况
职称：博士，副主任医师、硕士生导师
专业特长：肝癌的外科治疗、介入治疗、靶向免疫治疗等，肝转移的外科治疗。

学术兼职：
广东省抗癌协会肝癌专业委员会青委会 委员
广东省抗癌协会大肠癌专业委员会青委会 委员

工作概况：
　　自2007年以来，长期从事肝癌的临床诊治及相关研究工作，熟练掌握包括外科治疗、介入治疗、靶向治疗、免疫治疗等综合治疗手段。积极推进肝癌的临床研究开展，尤其是在不可切除肝癌的手术转化治疗、复杂疑难肝癌的综合治疗具有较为丰富的临床工作积累。在肠癌肝转移瘤的外科治疗方面，已有相当丰富的工作经验。

科研项目情况：
　　主持和承担包括国家自然科学基金在内的多项科研项目。包括：
(1)国家自然科学基金青年项目 名称:ZBED9在肝癌侵袭转移中的作用及机制研究， 批准号:**，经费22万元，2019.01～2021.12， 主持
(2) 广东省肝病研究重点实验室开放课题：初步探讨Rfx6调控肝癌干细胞的机制研究，项目编号：GS，经费：2****民币，2018.01～2019.12，主持
(3) 中山大学青年教师培养项目：ZBED9在肝癌侵袭转移中的作用及机制研究，经费15万元，2019.01～2020.12， 主持
(4) 国家自然科学基金面上项目：NCOA3上调端粒酶逆转录酶促进肝癌生长的分子机制及其临床意义， 批准号:**，经费55万元，2019.01～2022.12， 参与
(5) 国家自然科学基金面上项目：S100A9通过EMT调控肝细胞癌侵袭转移的机制研究，项目编号：**，经费：55.00万元，2020.01～2023.12， 参与
(6) 国家自然科学基金面上项目：Rfx6在肝癌干细胞干性特征维持中的作用及机制研究，项目编号：**，经费：90****民币，2014.01～2017.12，参与

代表性研究成果：
(1) Jiliang Qiu#, Baogang Peng#, Yunqiang Tang#, Yeben Qian#, Pi Guo#, Mengfeng Li, Junhang Luo, Bin Chen, Hui Tang, Canliang Lu, Muyan Cai, Zunfu Ke, Wei He, Yun Zheng, Dan Xie, Binkui Li*, Yunfei Yuan*. A CpG Methylation Signature Predicts Recurrence in Early-Stage Hepatocellular Carcinoma: Results From a Multicenter Study. J Clin Oncol 2017, 35(7):734-742 (2017 IF=26.303)
(2) Pinghua Yang#, Jiliang Qiu#, Jun Li#, Dong Wu, Xuying Wan, Wan Yee Lau, Yunfei Yuan*, Feng Shen*. Nomograms for Pre- and Postoperative Prediction of Long-term Survival for Patients Who Underwent Hepatectomy for Multiple Hepatocellular Carcinomas. Ann Surg. 2016, 263(4):778-86. (2016 IF=8.98)
(3) Yongxin Zhang #, Xiaofei Lv #, Jiliang Qiu #, Bin Zhang#, Lu Zhang, Jin Fang, Minmin Li, Luyan Chen, Fei Wang, Shuyi Liu, Shuixing Zhang*. Deep Learning With 3D Convolutional Neural Network for Noninvasive Prediction of Microvascular Invasion in Hepatocellular Carcinoma. J Magn Reson Imaging. 2021 Epub. (2020 IF= 3.732)
(4) Chenwei Wang#, Yadi Liao#, Jiliang Qiu#, Yichuan Yuan, Yangping Zhang, Kai Li, Ruhai Zou, Yongjing Wang, Dinglan Zuo, Wei He, Yun Zheng, Binkui Li*, Yunfei Yuan*. Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study. J Cancer Res Clin Oncol. 2020 146(10):2669-2680 (2020 IF= 3.332)
(5) Yi Li, Qingan Zeng, Jiliang Qiu, Ting Pang, Jianzhong Xian, Xuexia Zhang*. Long non-coding RNA UCA1 promotes breast cancer by upregulating PTP1B expression via inhibiting miR-206. Cancer Cell Int. 2019 1;19:275. (2019 IF= 4.175)
(6) Yi Li#, Jiliang Qiu#, Ting Pang, Zhixing Guo, Yonghui Su, Qingan Zeng, Xuexia Zhang*. Restoration of Arpin suppresses aggressive phenotype of breast cancer cells. Biomed Pharmacother. 2017 92:116-121 (2017 IF=3.457)
(7) Jiliang Qiu#, Yun Zheng#, Jingxian Shen, Zeng QingAn, Ruhai Zou, Yadi Liao, Wei He, Qijiong Li, Guihua Chen, Binkui Li, Yunfei Yuan*. Resection versus ablation in hepatitis B virus-related hepatocellular carcinoma patients with portal hypertension: A propensity score matching study. Surgery. 2015, 158(5):1235-1243.（2015 IF=3.309）
(8) Jiliang Qiu#, Mogeng Deng#, Wei Li, Ruhai Zou, Binkui Li, Yun Zheng, Xiangming Lao, Kai Zhou, Yunfei Yuan*. Hepatic Resection for Synchronous Hepatic Metastasis from Gastric Cancer. Eur J Surg Oncol 2013, 39:694-700 (2013 IF=2.892)
(9) Yan Li, Leilei Chen, Tim Hon Man Chan, Ming Liu, Kar–Lok Kong, Jiliang Qiu, Yan Li, Yunfei Yuan*, Xinyuan Guan*. SPOCK1 Is Regulated by CHD1L and Blocks Apoptosis and Promotes HCC Cell Invasiveness and Metastasis in Mice. Gastroenterology 2013, 144:179-191 （2013 IF=13.926）
(10) Qing-an Zeng#, Jiliang Qiu#, Jian Hong, Yi Li, Shengping Li, Ruhai Zou, Pinzhu Huang, Binkui Li, Yun Zheng, Xiangming Lao, Yunfei Yuan*. Hepatectomy for hepatocellular carcinoma patients with macronodular cirrhosis. Eur J Gastroenterol Hepatol 2012, 24(5):575-82. (2012 IF=1.915)
(11) Jiliang Qiu#, Pinzhu Huang#, Jing-Hong You, Ru-Hai Zou, Li Wang, Jian Hong, Binkui Li, Kai Zhou, Yunfei Yuan*. LIN28 expression and prognostic value in hepatocellular carcinoma patients who meet the Milan criteria and undergo hepatectomy. Chin J Cancer 2012, 31(5):223-232. (2014, IF=2.155)
(12) Pinzhu Huang#, Jiliang Qiu#, Jinghong You, Jian Hong, Binkui Li, Kai Zhou, Guihua Chen, Yunfei Yuan, Ruhai Zou*. Expression and prognostic significance of CIP2A mRNA in hepatocellular carcinoma and nontumoral liver tissues. Biomarkers. 2012, 17(5):422-9. (2012, IF=2.215)
(13) Qing-An Zeng#, Jiliang Qiu#, Ruhai Zou, Yijie Li, Shengping Li, Binkui Li, Pinzhu Huang, Jian Hong, Yun Zheng, Xiangming Lao, Yunfei Yuan*. Clinical features and outcome of multiple primary malignancies involving hepatocellular carcinoma: A long-term follow-up study. BMC Cancer 2012, 12(1):148. (2012 IF=3.333)
(14) Jiliang Qiu#, Pinzhu Huang#, Qian Liu#, Jian Hong, Binkui Li, Canliang Lu, Li Wang, Jianping Wang, Yunfei Yuan*. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med 2011, 9:166. (2011 IF=3.474)
(15) Pinzhu Huang#, Jiliang Qiu#, Binkui Li, Jian Hong, Canliang Lu, Li Wang, Jianping Wang, Yezhu Hu, Weihua Jia, Yunfei Yuan*. Role of Sox2 and Oct4 in predicting survival of hepatocellular carcinoma patients after hepatectomy. Clin Biochem 2011, 44:582-589. (2011 IF=2.076)
(16) Canliang Lu#, Jiliang Qiu#, Pinzhu Huang, Ruhai Zou, Jian Hong, Binkui Li, Guihua Chen, Yunfei Yuan*. NADPH Oxidase DUOX1 and DUOX2 but not NOX4 are independent predictors in hepatocellular carcinoma after hepatectomy. Tumor Biology 2011, 32(6):1173-1182. (2011 IF=2.143)

更新日期：2021年3月1日